Gene:
CEBPE
CCAAT/enhancer binding protein (C/EBP), epsilon

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

Overview

Alternate Names:  None
Alternate Symbols:  CRP1
PharmGKB Accession Id: PA26379

Details

Cytogenetic Location: chr14 : q11.2 - q11.2
GP mRNA Boundary: chr14 : 23586515 - 23588820
GP Gene Boundary: chr14 : 23583515 - 23598820
Strand: minus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.
No related genes are available

Curated Information ?

Evidence Drug Class
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
antineoplastic agents

Curated Information ?

Publications related to CEBPE: 2

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015. Pui Ching-Hon, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Novel Susceptibility Variants at 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethnically Diverse Populations. Journal of the National Cancer Institute. 2013. Xu Heng, et al. PubMed

LinkOuts

NCBI Gene:
1053
OMIM:
245480
600749
UCSC Genome Browser:
NM_001805
RefSeq RNA:
NM_001805
RefSeq Protein:
NP_001796
RefSeq DNA:
NG_009617
NT_026437
UniProtKB:
CEBPE_HUMAN (Q15744)
Ensembl:
ENSG00000092067
GenAtlas:
CEBPE
GeneCard:
CEBPE
MutDB:
CEBPE
ALFRED:
LO019977H
HuGE:
CEBPE
Comparative Toxicogenomics Database:
1053
ModBase:
Q15744
HumanCyc Gene:
HS01755
HGNC:
1836

Common Searches